Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Humacyte, Inc.NASDAQ: HUMA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 197.85M shares rose 50.2% year over year, ahead of the +37.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 25.1% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +50.2% holds above the trailing-twelve-month pace of +37.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
197.85M+25.1% QoQ
Last fiscal yearDec 2025
158.16M+33.5% YoY
LTMMar 2026
167.44M+37.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.2%——
1 year+33.5%——
3-year CAGR+15.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
158.16M USD
Year-over-year change
+33.5%
4-year CAGR
+41.0%

Weighted Avg Shares (Diluted) vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 weighted avg shares (diluted) of 167.44M shares is the highest of the 11 companies compared; the peer median is 53.5M shares.
  • Its year-over-year change of +37.0% is the 2nd highest of 11, against a peer median of +1.7%.
  • Over three fiscal years its annual growth of +15.3% compares with a peer median of +11.6%.
HUMA Competitors Peer median
Weighted Avg Shares (Diluted) for HUMA and competitors
Company Period LTM YoY 3-year CAGR
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.0%+15.3%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
ACHVAchieve Life Sciences, Inc.LTM Mar 202648.09M +39.5%+60.3%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +3.6%+9.8%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
Peer median (excluding HUMA) 53.5M+1.7%+11.6%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.26M1.57M002.04M
Cost of Revenue61.34M8.26M76.55M7.19M17.05M
Gross Profit(60.08M)(6.69M)(76.55M)(7.19M)(15.01M)
Gross Margin-4756.8%-427.5%——-736.5%
Research & Development61.34M63.26M76.55M88.6M69.3M
Selling, General & Admin21.13M22.88M20.39M25.8M31.17M
Operating Expenses21.13M77.89M23.5M107.21M92.43M
Depreciation & Amortization8.24M8.21M7.72M7.19M7.35M
EBITDA(13.89M)2.45M(96.46M)(132.23M)(22.24M)
EBITDA Margin-1099.6%156.2%——-1091.2%
Operating Income(81.21M)(84.58M)(100.05M)(114.4M)(107.44M)
Operating Margin-6429.8%-5404.3%——-5271.7%
Interest Income16K2.63M5.47M4.1M2.59M
Interest Expense4.35M6.2M6.6M9.28M11.25M
Other Income / Expenses54.73M72.61M(10.73M)(34.3M)66.6M
Income Before Tax(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Pre-Tax Margin-2096.4%-764.5%——-2003.6%
Income Tax Expense00000
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Net Margin-2096.4%-764.5%——-2003.6%
EPS (Basic)(0.66)(0.12)(1.07)(1.26)(0.26)
EPS (Diluted)(0.66)(0.12)(1.07)(1.26)(0.26)
Weighted Avg Shares39.97M103.05M103.42M118.48M158.16M
Weighted Avg Shares (Diluted)39.97M103.05M103.42M118.48M158.16M

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.